Background Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia …

Background Streptococcus pneumoniae is a major cause of morbidity and mortality among
adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are …

Background. High functional antibody responses, establishment of immunologic memory,
and unambiguous efficacy in infants suggest that an initial dose of conjugated …

Introduction A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to
expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the …

A 13-valent pneumococcal conjugate vaccine has been studied in adults aged≥ 50 years to
compare the immune response to that induced by the 23-valent pneumococcal …

Background In early 2000, a protein–polysaccharide conjugate vaccine targeting seven
pneumococcal serotypes was licensed in the United States for use in young children …

Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and
bacterial meningitis. Although effective antimicrobial drugs have reduced case fatality, the …

In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent
pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal …

Background A pneumococcal conjugate vaccine (PCV) specifically focused on serotypes
associated with adult residual disease burden is urgently needed. We aimed to assess …

Background The currently recommended single dose of the 23-valent pneumococcal free
polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide …